Company Performance Metrics
MediCrops® Group is a Swiss-based, vertically integrated pharmaceutical group focused on redefining patient access to medical cannabis and advanced therapeutic solutions across Europe. Founded in 2018, the company operates a fully licensed supply chain with core subsidiaries including a Swissmedic-certified compounding pharmacy, a national
telemedicine platform, and a specialized import & distribution unit for cannabinoid-based APIs.
With operations spanning B2B and D2C channels, MediCrops® delivers standardized medical cannabis products (flowers, extracts, capsules) under strict Swiss pharmaceutical regulations. Through its proprietary telehealth brand, patients gain remote access to therapy initiation, medical prescriptions, and pharmaceutical services — seamlessly integrated under one roof.
MediCrops® Group empowers physicians, pharmacists, and patients by combining regulatory excellence, digital infrastructure, and scalable therapeutic protocols. With over 50 employees across Switzerland and international partnerships in Germany, the Netherlands, and Portugal, the Group is positioned to lead Europe’s next generation of cannabis-based care and pharmaceutical innovation.
